ArticleClinical infectious diseases : an official publication of the Infectious Diseases Society of America2021
Outcomes Associated With Medications for Opioid Use Disorder Among Persons Hospitalized for Infective Endocarditis.
Article in Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 44 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
44 citing papers in PubMed, 62 citations in OpenAlex.
- Hospital admissions among patients with Comorbid Substance Use disorders: a secondary analysis of predictors from the NavSTAR Trial.Addiction science & clinical practice · 2024Trial
- Insurance Status and Quality of Care in Infective Endocarditis: A National Analysis of Disparities in Length of Stay, Discharge, and Mortality.Journal of clinical medicine · 2026Article
- Integrated infectious disease and substance use disorder treatment for severe injection-related infections: protocol for the randomized controlled HI-SIRI trial.Addiction science & clinical practice · 2026Article
- Improving hospital-based care for patients with injection-drug related infections: provider perspectives.Addiction science & clinical practice · 2026Article
- Clinical Impact of an Expanded MOUD Access Initiative for Patients Hospitalized With Infections From Intravenous Opioid Use.American journal of medicine open · 2025Article
- Endocarditis: Rising Incidence in the Post-COVID-19 Pandemic Era: A Narrative Review.Journal of clinical medicine · 2025Review
- Sensitivity and Specificity of Natural Language Processing Systems for Identification of Hospitalized People Who Use Drugs.Open forum infectious diseases · 2025Article
- Impact of Substance Use Disorders on Outcomes of Medically Insured Persons Receiving Multiweek Outpatient Parenteral Antimicrobial Therapy: a Claims-based Cohort Study From 2015 to 2020.Open forum infectious diseases · 2025Article
- Risk Factors for Infective Endocarditis and Serious Injection Related Infections Among People Who Inject Drugs in Los Angeles, CA and Denver, CO.Drug and alcohol dependence · 2025Article
- Association Between Inpatient Medication Treatment for Opioid Use Disorder and Reduced One-Year All-Cause Mortality in Patients With Invasive Bacterial Infections.Open forum infectious diseases · 2025Article
- Medication for Opioid Use Disorder After Serious Injection-Related Infections in Massachusetts.JAMA network open · 2024Article
- Out-of-pocket spending and health care utilization associated with initiation of different medications for opioid use disorder: Findings from a national commercially insured cohort.Journal of substance use and addiction treatment · 2024Article
- Real-World Dalbavancin Use for Serious Gram-Positive Infections: Comparing Outcomes Between People Who Use and Do Not Use Drugs.Open forum infectious diseases · 2024Article
- Opportunities to improve opioid use disorder care for hospitalised patients with endocarditis.BMJ open quality · 2023Article
- The Impact of Discharge Against Medical Advice on Readmission After Opioid Use Disorder-Associated Infective Endocarditis: a National Cohort Study.Journal of general internal medicine · 2023Article
- Eliminate the buprenorphine DEA X waiver: Justification using a policy analysis approach.Journal of nursing scholarship : an official publication of Sigma Theta Tau International Honor Society of Nursing · 2023Article
- Implementation of an integrated infectious disease and substance use disorder team for injection drug use-associated infections: a qualitative study.Addiction science & clinical practice · 2023Article
- Integrated Infectious Disease and Substance Use Disorder Care for the Treatment of Injection Drug Use-Associated Infections: A Prospective Cohort Study With Historical Control.Open forum infectious diseases · 2023Article
- Methamphetamines and Serious Injection-Related Infections: Opioid Use Care Continuum and Opportunities to End Alabama's Drug Crisis.Open forum infectious diseases · 2023Article
- Article
Corrections and comments
- Commented on by
Authors and funding
6 authors at 3 institutions in 1 country.
Funding
Abstract
backgroundEndocarditis, once predominately found in older adults, is increasingly common among younger persons who inject drugs. Untreated opioid use disorder (OUD) complicates endocarditis management. We aimed to determine if rates of overdose and rehospitalization differ between persons with OUD with endocarditis who are initiated on medications for OUD (MOUDs) within 30 days of hospital discharge and those who are not.
methodsWe performed a retrospective cohort study using a large commercial health insurance claims database of persons ≥18 years between July 1, 2010, and June 30, 2016. Primary outcomes included opioid-related overdoses and 1-year all-cause rehospitalization. We calculated incidence rates for the primary outcomes and developed Cox hazards models to predict time from discharge to each primary outcome as a function of receipt of MOUDs.
resultsThe cohort included 768 individuals (mean age 39 years, 51% male). Only 5.7% of people received MOUDs in the 30 days following hospitalization. The opioid-related overdose rate among those who did receive MOUDs in the 30 days following hospitalization was lower than among those who did not (5.8 per 100 person-years [95% confidence interval [CI], 5.1-6.4] vs 7.3 per 100-person years [95% CI, 7.1-7.5], respectively). The rate of 1-year rehospitalization among those who received MOUDs was also lower than those who did not (162.0 per 100 person-years [95% CI, 157.4-166.6] vs 255.4 per 100 person-years [95% CI, 254.0-256.8], respectively). In the Cox hazards models, the receipt of MOUDs was not associated with either of the outcomes.
conclusionsMOUD receipt following endocarditis may improve important health-related outcomes in commercially insured persons with OUD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.